Concert Pharmaceuticals, Inc. (CNCE): Thomas G Auchincloss , director of Concert Pharmaceuticals, Inc. purchased 2,000 shares on May 12, 2016. The Insider buying transaction was reported by the company on May 16, 2016 to the Securities and Exchange Commission. The shares were purchased at $10.11 per share for a total value of $20,211.20 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on May 12, 2016, Roger D Tung (CEO) purchased 19,610 shares at $10.55 per share price.On Dec 17, 2015, Richard Aldrich (director) sold 20,000 shares at $19.76 per share price.Also, On Dec 15, 2015, Pauline Mcgowan (VP, Finance) sold 498 shares at $20.07 per share price.On Nov 10, 2015, Ronald W Barrett (director) sold 17,699 shares at $22.33 per share price.
Concert Pharmaceuticals Inc: On Friday, May 13, 2016 heightened volatility was witnessed in Concert Pharmaceuticals Inc which led to swings in the share price. The shares opened for trading at $10.24 and hit $11.32 on the upside , eventually ending the session at $11.13, with a gain of 9.87% or 1 points. The heightened volatility saw the trading volume jump to 1,54,912 shares. The 52-week high of the share price is $25.04 and the company has a market cap of $247 M . The 52-week low of the share price is at $9.81.
Concert Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company applying its DCE Platform to create novel small molecule drugs. The Company’s approach starts with approved drugs advanced clinical candidates or previously studied compounds that have the potential to be improved with deuterium substitution to enhance clinical safety tolerability and efficacy. It has a pipeline of wholly owned and collaboration programs. The Company has a number of clinical candidates under development such as CTP-656 which is a product candidate for the treatment of cystic fibrosis; AVP-786 which is being investigated for treatment of neurologic and psychiatric disorders including Alzheimers agitation; CTP-730 which is a product candidate for the treatment of inflammatory diseases and JZP-386 which is a product candidate for the treatment of narcolepsy.